Barely eating on Mounjaro and still not losing weight

What the trial data actually shows about early and stalled loss

SURMOUNT-1, the phase-3 trial published in the New England Journal of Medicine, followed thousands of adults using tirzepatide over 72 weeks. The average body-weight reduction at the highest dose reached around 20–21%, but that figure obscures a less-quoted truth: weight loss was not uniform across those 72 weeks. The steepest drops tended to come after dose increases, with slower periods in between. Participants who saw little movement in the first four to eight weeks often went on to achieve significant loss later.

The NHS tirzepatide information page is clear that Mounjaro works by activating two gut-hormone receptors (GIP and GLP-1) to reduce appetite and slow gastric emptying. But appetite reduction alone does not guarantee the scales will move on a given week. If you're eating very little and still not losing, the explanation usually sits in one of three areas: where your body is drawing its energy from, what it's doing with water, or how well your current dose matches your physiology.

A note that our prescribers hear most weeks: people often assume the problem is that Mounjaro has stopped working, when the pattern they're describing is actually a documented mid-treatment plateau rather than treatment failure. That distinction matters enormously for what to do next.

Severe restriction can work against weight loss on Mounjaro

This is counterintuitive, but it has solid grounding. When someone eats very little for an extended stretch (below roughly 800–1,000 kcal daily, for example) the body can shift into a conservation state. Resting metabolic rate falls. The body preferentially breaks down lean tissue alongside fat, meaning weight on the scale may not change even as muscle is lost. That muscle loss then lowers the total daily energy expenditure further, creating a cycle that makes future loss harder.

On tirzepatide, appetite is often so blunted that eating almost nothing can feel natural. It isn't. NHS England's guidance on weight-management injections stresses the importance of adequate protein intake, hydration and physical activity alongside treatment, precisely because under-eating while on these medicines is a real and under-discussed risk. A rough target of 1.2–1.6 g of protein per kilogram of body weight per day, spread across meals, helps preserve muscle. If you're eating so little that hitting that figure feels impossible, your prescriber needs to know.

For more on the pattern of restricted eating alongside Mounjaro without the expected results, the not eating on Mounjaro but not losing weight page covers this overlap in more detail.

Other reasons the number on the scale can stall

Water retention is one of the most common culprits and one of the least discussed. Glycogen (the stored form of carbohydrate in muscle and liver) holds roughly three grams of water for every gram of glycogen. As carbohydrate intake drops sharply (which happens naturally when appetite falls), glycogen stores deplete and you lose water weight quickly at first. Then, when you begin eating slightly more, or when stress or poor sleep causes cortisol to rise, glycogen and water can return almost overnight. The scales go up or stay flat while actual fat loss continues underneath.

Constipation is also relevant. It's one of the more common gastrointestinal side effects of tirzepatide, and a backed-up bowel can add a kilogram or two of apparent weight at any given weigh-in. Slow gastric emptying (the same mechanism that blunts appetite) slows the whole digestive system.

Dose is a separate issue worth naming plainly. If you are still on 2.5mg or 5mg, the trial evidence is unambiguous: the biggest results appeared at higher doses. The early titration steps exist to let your system adapt, not to produce large losses. If your dose hasn't moved in several months, that is a clinical conversation to have. The timeline for Mounjaro to start working page sets realistic expectations by dose stage.

Tracking method matters too. Weigh at the same time of day (morning, after using the bathroom, before eating) on the same surface, and look at the trend across four weeks rather than any single reading. Week-to-week variance of one to two kilograms from fluid alone is entirely normal.

When to talk to your prescriber, and what happens next

If you have been on a stable dose for 12 or more weeks, eating consistently, and have seen less than 3–4% body-weight change, that is worth raising with whoever manages your treatment. NICE's guidance on tirzepatide (TA1026) sets a review point at six months on the highest tolerated dose: if less than 5% weight loss has occurred by then, continued treatment is reviewed. That is the formal threshold, but there's no reason to wait that long if something doesn't feel right.

A prescriber can assess whether the dose is appropriate for where you are, check for other factors (thyroid function, medication interactions, sleep, activity), and help you understand whether what's happening is a stall, a plateau, or something that needs a different approach entirely. If you're taking Mounjaro and the weight simply isn't shifting despite doing everything right, that page walks through the most likely clinical explanations and what to discuss with your prescriber. They can also review whether your calorie intake has dropped to a level that is undermining rather than supporting your progress.

If you're looking at the cost of private treatment alongside all of this, the Mounjaro price comparison page sets out what different providers charge and what those prices typically include, useful context if you're deciding where to continue treatment. For a broader picture of why weight loss on Mounjaro can stall, including factors beyond diet, that page covers the full picture. And if you're weighing up treatment options or want to speak to a prescriber about your specific situation, you can start a free consultation with our clinical team. If the scales haven't budged at all since starting, the not losing any weight on Mounjaro page looks specifically at cases where progress has been entirely absent rather than just slower than expected.